ANNX_OUT_1 [2025-04-24 06:17:18 -0400] 6628 Bytes | 1752 tokens | Cum: 1752 tkns (21.90% of 8k)
==========================================================================

We are in the 'Lightning Round' baby! It's 6:17 AM on Thu Apr 24, 2025, and I'm firing up the spotlight on Annexon (ANNX), moving from $1.46 to $1.68. Is this a can’t-miss rocket or a one-hit wonder? Let’s dissect the numbers!

--- COMPANY PROFILE ---
Company: Annexon (ANNX)
IPO: 2020-07-24 (4 Years Ago)
Market Cap: $154,142,306
Shares Outstanding: 109,710,000
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS
Description: Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

Here’s a list of headlines for Annexon:

Apr-16-25 04:05PM - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Apr-15-25 07:12AM - Annexon: With IGOS Study Completion, Pre-BLA Meeting In 1st Half 2025 On Deck
Apr-10-25 09:24AM - Why Annexon Inc. (ANNX) Went Down On Thursday?
Apr-09-25 03:20PM - Annexon's Investigational Drug Shows Rapid Recovery And Durable Benefit In Rare Neurological Disorder
Apr-08-25 04:05PM - Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barr Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
Apr-08-25 04:05PM 04:05PM - Annexon Highlights Pivotal Data on First Potential Targeted Therapy for Guillain-Barre Syndrome (GBS) and Showcases New GBS Education Campaign at American Academy of Neurology (AAN) 2025 Annual Meeting
Apr-03-25 06:18PM - Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barr Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
Apr-03-25 06:18PM 06:18PM - Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barre Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
Mar-17-25 04:05PM - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)
Mar-16-25 06:05AM - Wells Fargo Predicts Up to ~440% Rally for These 2 Strong Buy Stocks
Mar-03-25 08:00AM - Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
Feb-26-25 04:05PM - Annexon Biosciences to Present at the TD Cowen 45th Annual Health Care Conference
Feb-18-25 08:00AM - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Feb-13-25 08:30AM - Annexon Announces Presentations Highlighting ANX007 Functional and Structural Differentiation in Geographic Atrophy at the Macula Society 48th Annual Meeting
Jan-13-25 08:00AM - Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
Jan-10-25 08:00AM - Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones
Jan-07-25 08:00AM - Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Dec-16-24 04:05PM - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
Dec-16-24 04:05PM 07:30AM - Annexon Announces Positive Topline Results from Real-World Evidence Study Comparing ANX005 Treatment to Intravenous Immunoglobulin (IVIg) or Plasma Exchange (PE) in a Matched Patient Cohort for the Treatment of Guillain-Barr Syndrome (GBS)
Dec-05-24 08:00AM - Annexon to Present Phase 2 ARCHER Data on Protection of Vision and Photoreceptors with ANX007 in Geographic Atrophy at the Floretina-ICOOR 2024 Meeting
Nov-19-24 03:00AM - The Dodgers World Series run brought attention to a rare disease. Annexon is stepping up to the plate.
Nov-15-24 04:59PM - Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Here's another list of headlines with menu handles.
I will deliver the full text of the following stories when you say their handle.
Just say, for example, B1, B2, etc.

B1 - 2025-04-03T22:18:00Z - Annexon Highlights Leadership in Advancing Clinical Research and Education for Guillain-Barré Syndrome (GBS) at American Academy of Neurology (AAN) 2025 Annual Meeting
B2 - 2025-01-07T13:00:00Z - Annexon Biosciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
B3 - 2024-07-11T22:10:35Z - Annexon to Present Additional Phase 2 Data Showing Preservation of Visual Function and Structure by ANX007 in Geographic Atrophy at the 42nd ASRS Annual Scientific Meeting - GlobeNewswire
B4 - 2024-06-28T13:40:11Z - Are Medical Stocks Lagging Annexon (ANNX) This Year?
B5 - 2024-06-27T13:55:02Z - Here's Why Annexon (ANNX) Is a Great 'Buy the Bottom' Stock Now
B6 - 2024-06-25T21:00:00Z - Annexon Presented Additional Positive Phase 3 Results for ANX005 C1q-Targeted Immunotherapy in Guillain-Barré Syndrome at the 2024 PNS Annual Meeting

==============
-> THE ROLE FOR AI:
==============

1) You are the **AI analyst-investigator**, and this interaction represents a full **due diligence session** for Annexon (ANNX).
Due diligence includes financial data, insider trading, relevant news, and any SEC filings — and may extend beyond classic fundamentals.
Your task is to identify whether this stock has momentum and potential.

2) I am **ScanScor**, a unified report generator that archives this session as part of our real-time diligence record.

3) You will request information by referencing documents by their code.

4) As the analysis proceeds, your are encouraged to review documents until you feel confident in your judgment.
After seeing 3 sets of news articles, SEC docs, and financials, you'll be prompted to return some data pairs.

5) News articles, SEC filings, and key metrics will be revealed in subsequent prompts.

Stay focused. Gather evidence. Continue until your conclusions are clear.
Restrict all your responses to just 3 tokens until the summary and data pairs at the end.

NEXT: Request a document with its reference code(s), such as:
- `B1`, `B2`, `B3`, etc.
- To load a new set of information and menu options, reply with: `NEX`

ANNX_OUT_3 [2025-04-24 06:17:19 -0400] 925 Bytes | 288 tokens | Cum: 2042 tkns (25.52% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-23T10:54:16Z - Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Bain Capital Life Sciences Investors LLC...
A2 - 2025-04-20T08:36:51Z - Annexon, Inc. (NASDAQ:ANNX) Stock Position Increased by Walleye Capital LLC...
A3 - 2025-04-20T06:46:04Z - Annexon, Inc. (NASDAQ:ANNX) Sees Large Decrease in Short Interest...
A4 - 2025-04-19T07:14:00Z - JPMorgan Chase & Co. Has $7.75 Million Position in Annexon, Inc. (NASDAQ:ANNX)...
A5 - 2025-04-16T20:06:23Z - Annexon Reports Inducement Grant to New Employee Under Nasdaq Listing Rule 5635(c)(4)...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

ANNX_OUT_5 [2025-04-24 06:17:20 -0400] 1181 Bytes | 334 tokens | Cum: 2378 tkns (29.73% of 8k)
==========================================================================

Showing A1 (chunk 1 of 5): A1:
**Annexon, Inc. (NASDAQ:ANNX) Shares Sold by Bain Capital Life Sciences Investors LLC**Date: 2025-04-23Source: {'uri': 'marketbeat.com', 'dataType': 'news', 'title': 'Market Beat'}URL: https://www.marketbeat.com/instant-alerts/annexon-inc-nasdaqannx-shares-sold-by-bain-capital-life-sciences-investors-llc-2025-04-21/Bain Capital Life Sciences Investors LLC reduced its stake in shares of Annexon, Inc. (NASDAQ:ANNX - Free Report) by 37.9% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 5,249,069 shares of the company's stock after selling 3,200,679 shares during the period. Annexon makes up approximately 3.2% of Bain Capital Life Sciences Investors LLC's holdings, making the stock its 9th biggest holding. Bain Capital Life Sciences Investors LLC owned 4.92% of Annexon worth $26,928,000 as of its most recent SEC filing.

Several other institut

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_7 [2025-04-24 06:17:21 -0400] 1181 Bytes | 302 tokens | Cum: 2682 tkns (33.52% of 8k)
==========================================================================

Showing A1 (chunk 2 of 5): ional investors and hedge funds also recently made changes to their positions in the stock. E Fund Management Co. Ltd. lifted its position in Annexon by 36.0% in the 4th quarter. E Fund Management Co. Ltd. now owns 15,447 shares of the company's stock valued at $79,000 after acquiring an additional 4,086 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Annexon by 1.8% during the fourth quarter. Wellington Management Group LLP now owns 268,166 shares of the company's stock worth $1,376,000 after buying an additional 4,806 shares during the period. Rhumbline Advisers grew its holdings in shares of Annexon by 4.3% during the fourth quarter. Rhumbline Advisers now owns 141,852 shares of the company's stock worth $728,000 after buying an additional 5,854 shares in the last quarter. Bank of New York Mellon Corp raised its position in Annexon by 2.8%

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_9 [2025-04-24 06:17:24 -0400] 1181 Bytes | 324 tokens | Cum: 3008 tkns (37.60% of 8k)
==========================================================================

Showing A1 (chunk 3 of 5): in the 4th quarter. Bank of New York Mellon Corp now owns 230,546 shares of the company's stock valued at $1,183,000 after buying an additional 6,226 shares during the last quarter. Finally, MetLife Investment Management LLC lifted its stake in Annexon by 17.7% in the 4th quarter. MetLife Investment Management LLC now owns 64,967 shares of the company's stock valued at $333,000 after acquiring an additional 9,755 shares in the last quarter.

Separately, Needham & Company LLC reaffirmed a "buy" rating and set a $16.00 price target on shares of Annexon in a research note on Tuesday, March 4th.

Check Out Our Latest Stock Analysis on ANNX

Shares of NASDAQ ANNX opened at $1.46 on Monday. The business has a 50-day moving average of $2.28 and a 200-day moving average of $4.39. The stock has a market capitalization of $160.18 million, a price-to-earnings ratio of -1.39 and a beta of 1.24. Ann

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_11 [2025-04-24 06:17:25 -0400] 1182 Bytes | 292 tokens | Cum: 3302 tkns (41.27% of 8k)
==========================================================================

Showing A1 (chunk 4 of 5): exon, Inc. has a fifty-two week low of $1.29 and a fifty-two week high of $7.85.

Annexon (NASDAQ:ANNX - Get Free Report) last posted its quarterly earnings results on Monday, March 3rd. The company reported ($0.33) earnings per share for the quarter, missing the consensus estimate of ($0.28) by ($0.05). On average, sell-side analysts expect that Annexon, Inc. will post -0.96 EPS for the current year.

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

This instant news alert was g

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_13 [2025-04-24 06:17:25 -0400] 1104 Bytes | 237 tokens | Cum: 3541 tkns (44.26% of 8k)
==========================================================================

Showing A1 (chunk 5 of 5): enerated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].

Before you consider Annexon, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Annexon wasn't on the list.

While Annexon currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_15 [2025-04-24 06:17:27 -0400] 1085 Bytes | 284 tokens | Cum: 3827 tkns (47.84% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

S1 - 2025-03-03 8-K Item 2.02. Results of Oper and Fin Cond.

On March 3, 2025, Annexon, Inc. (the Company) announced certain financial results for the fourth quarter and the year ended December 31, 2024. A copy of the Companys press release, titled Annexon Reports Fourth Quarter a...

S8 - 2025-03-03 8-K Item 2.02. Results of Oper and Fin Cond.

On March 3, 2025, Annexon, Inc. (the Company) announced certain financial results for the fourth quarter and the year ended December 31, 2024. A copy of the Companys press release, titled Annexon Reports Fourth Quarter a...

S9 - 2025-03-03 10-K Item 7. Mgts Discussion and Analysis of Fin Cond and Results of Oper.

You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our CONS financial statements and the related no...

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

ANNX_OUT_17 [2025-04-24 06:17:28 -0400] 1181 Bytes | 309 tokens | Cum: 4138 tkns (51.73% of 8k)
==========================================================================

Showing S1 (chunk 1 of 2): S1:
Item 2.02. Results of Operations and Financial Condition.

On March 3, 2025, Annexon, Inc. (the Company) announced certain financial results for the fourth quarter and the year ended December 31, 2024. A copy of the Companys press release, titled Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones is furnished pursuant to Item 2.02 as Exhibit 99.1 hereto.

The information in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Section 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be incorporated by reference into

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_19 [2025-04-24 06:17:29 -0400] 547 Bytes | 133 tokens | Cum: 4273 tkns (53.41% of 8k)
==========================================================================

Showing S1 (chunk 2 of 2): any filing with the U.S. Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing, except as expressly set forth by specific reference in such a filing....

Respond with ONLY ONE of the following (3 characters max):
- `MOR` to continue this item
- `NEX` to move to the next set of documents
- `C2`, `S3`, etc. to request another document
**DO NOT SUMMARIZE. DO NOT EXPLAIN.** Wait until all data is presented.

ANNX_OUT_21 [2025-04-24 06:17:36 -0400] 6950 Bytes | 1966 tokens | Cum: 6243 tkns (78.04% of 8k)
==========================================================================

This is our set of metrics for Annexon.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+-----------------------+
| Volume: 3,178,064 | Perf Month: -31.85% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| Avg Volume: 1.71M | Perf Quarter: -55.66% | Short Float: 8.67% | ROE: -50.84% |
+-------------------+-----------------------+-------------------------+-----------------------+
| Rel Volume: 1.88 | Index: RUT | Short Ratio: 4.82 | ROI: -43.25% |
+-------------------+-----------------------+-------------------------+-----------------------+
| RSI (14): 46.96 | Market Cap: 201.87M | Short Interest: 8.24M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| ATR (14): 0.21 | Shs Outstand: 109.38M | Beta: 1.23 | EPS Surprise: -22.40% |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA20: 6.07% | Shs Float: 95.11M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA50: -19.99% | Inst Own: 90.99% | Sales past 5Y: 0.00% | Earnings: Mar 03 BMO |
+-------------------+-----------------------+-------------------------+-----------------------+
| SMA200: -62.45% | Insider Own: 13.31% | Employees: 100 | |
+-------------------+-----------------------+-------------------------+-----------------------+
| Perf Week: 19.48% | Insider Trans: -0.27% | Debt/Eq: 0.10 | |
+-------------------+-----------------------+-------------------------+-----------------------+

The next section covers any insider trading by Annexon officers or majority shareholders (if available).

Inside Trans: Annexon, Inc. (ANNX) by ARTIS DEAN RICHARD (EVP & CHIEF SCIENTIFIC OFFICER) on 2025-02-27
- Common Stock: 44963 shares at $0 (D)
- Stock Option (Right to Buy): 272575 shares at $0 (D)

Inside Trans: Annexon, Inc. (ANNX) by Dananberg Jamie (CHIEF MEDICAL OFFICER) on 2025-02-27
- Common Stock: 44963 shares at $0 (D)
- Stock Option (Right to Buy): 228225 shares at $0 (D)

Inside Trans: Annexon, Inc. (ANNX) by Lew Jennifer (EVP & CHIEF FINANCIAL OFFICER) on 2025-02-27
- Common Stock: 44963 shares at $0 (D)
- Stock Option (Right to Buy): 272575 shares at $0 (D)

Inside Trans: Annexon, Inc. (ANNX) by Love Douglas (PRESIDENT AND CEO) on 2025-02-27
- Stock Option (Right to Buy): 1300000 shares at $0 (D)

Inside Trans: Annexon, Inc. (ANNX) by Yednock Ted (EVP & CHIEF INNOVATION OFFICER) on 2025-02-27
- Common Stock: 44963 shares at $0 (D)
- Stock Option (Right to Buy): 272575 shares at $0 (D)

Inside Trans: Annexon, Inc. (ANNX) by Overdorf Michael (EVP & CHIEF BUSINESS OFFICER) on 2025-02-27
- Common Stock: 44963 shares at $0 (D)
- Stock Option (Right to Buy): 272575 shares at $0 (D)

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -117501000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.84
Average Volume: 2331009.1
30-Day High: 2.47
30-Day Low: 1.38

[Detailed Financials: Q3 2024]
- Total Assets: $378,776,000.00
- Total Liabilities: $47,216,000.00
- Total Equity: $331,560,000.00
- Current Assets: $344,292,000.00
- Current Liabilities: $20,046,000.00

[Income Statement: Q3 2024]
- Revenue: $0.00
- Net Income: $-34,824,000.00
- Gross Profit: N/A
- Operating Income: $-39,442,000.00
- Earnings Per Share (EPS): -0.25

[Cash Flow Statement: Q3 2024]
- Net Cash Flow: $-77,764,000.00

[Detailed Financials: Q2 2024]
- Total Assets: $406,085,000.00
- Total Liabilities: $45,006,000.00
- Total Equity: $361,079,000.00
- Current Assets: $373,969,000.00
- Current Liabilities: $17,148,000.00

[Income Statement: Q2 2024]
- Revenue: $0.00
- Net Income: $-29,610,000.00
- Gross Profit: N/A
- Operating Income: $-33,580,000.00
- Earnings Per Share (EPS): -0.23

[Cash Flow Statement: Q2 2024]
- Net Cash Flow: $5,363,000.00
==== END OF FINANCIAL REPORT ====

You are now requested to write a summary analysis of Annexon (ANNX).

Please complete the report using the exact format:
FIELD[value]

1) BRIEF_SUMMARY[]
One well-worded paragraph summarizing your findings about Annexon.

2) MARKET_SCORE[]
This conversation was initiated because ANNX is currently experiencing upward price and volume movement.
Estimate a number between 1–100 based on the likelihood of a continued upward price move for ANNX.
Weigh relevant data — news, filings, fundamentals, and metrics — and assign appropriate weight.

3) PRICE_TARGET[]
Suggest a price, based on all prior evidence and past price behavior, ANNX could reach in the current or upcoming trading sessions (1–5 days).
For example, if you expect ANNX to increase 50% from its current price of $0.00, say: PRICE_TARGET[0.0]

4) AI_RPT_HEADLINE[]
Write a thought-provoking 8–12 word headline summarizing this report.

5) SQUEEZE_POTENTIAL[]
Give a score from 1 to 100 representing the potential for this stock to become an active short squeeze play.
Be honest and unbiased. Consider short interest/float, price movement, volume, news strength, and volatility potential.

6) TAGS[]
List 3–6 comma-separated tags (e.g., biotech, earnings beat, squeeze setup)

7) STOCK_TYPE[]
Choose the most accurate classification: growth, value, turnaround, hype, squeeze, dividend, speculative, or other.

8) PRIMARY_CATALYST[]
e.g., earnings report, FDA approval, partnership, etc.

9) SENTIMENT[]
bullish, bearish, neutral, or mixed

10) IMPROVEMENT_SUGGESTION[]
If you believe some key info was missing, state what would have significantly improved your analysis of Annexon.

11) ETHICAL_RATING[]
Rate Annexon’s alignment with long-term shareholder interests, using a letter grade from A (high alignment) to F (low alignment).
Base this on actions such as insider buying/selling, share dilution, follow-through on public statements, and compensation practices.

12) UPCOMING_CATALYST[]
Specify any upcoming events you expect would be a catalyst affecting the share-price of Annexon.
Provide any reasons you can use to support it.

Return only: FIELD[value] for each of the above 12 questions.
Respond with all data pairs. Take your best guess if you have to, but don't leave blank items.
Do not explain your answers. Return only the required fields in the exact format shown.

Finally, thank you for participating!

ANNX_IN_23 [2025-04-24 06:17:36 -0400] 126 Bytes | 29 tokens | Cum: 6481 tkns (81.01% of 8k)
==========================================================================

====================================
[2025-04-24 06:17:36] # Analysis Completed
Elapsed Time: 19.13 seconds